Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Zealand Pharma Initiates DKK 1.3B...
Business share buy-back

Zealand Pharma Initiates DKK 1.3B Share Buy-Back

Analysis based on 8 articles · First reported May 07, 2026 · Last updated May 07, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The initiation of Zealand Pharma's DKK 1.3 billion share buy-back program is likely to be viewed positively by the market, potentially boosting investor confidence and the company's stock price. This action, coupled with expected significant milestone payments from Roche, signals strong financial health and a commitment to shareholder returns, which could attract further investment in Zealand Pharma and the biotechnology sector.

Biotechnology Pharmaceuticals
Event Summary

Zealand Pharma has announced the initiation of a DKK 1.3 billion (USD 200 million) share buy-back program, effective from May 7, 2026, to October 31, 2026. The program, managed by Danske Bank, aims to meet obligations from share-based incentive programs and reduce share capital. This decision is underpinned by Zealand Pharma's robust cash position of USD 2.3 billion and anticipated milestone payments of USD 700 million from Roche in 2026, including USD 575 million for the initiation of Phase 3 trials for petrelintide monotherapy. The company emphasizes its financial strength to invest in research and development for metabolic health while returning capital to shareholders.

Key Actions
100 Zealand Pharma initiates share buy-back
80 Zealand Pharma expects milestone payments Roche
30 Danske Bank appointed lead manager Zealand Pharma
Entities Involved
stock
Zealand Pharma
Zealand Pharma initiated a DKK 1.3 billion share buy-back program, demonstrating strong financial health and a commitment to returning capital to shareholders while investing in its metabolic health pipeline.
Importance 100 Sentiment 70
stock
Danske Bank
Danske Bank was appointed as the lead manager for Zealand Pharma's share buy-back program, making independent trading decisions within the program's terms.
Importance 30 Sentiment 0
stock
Roche
Zealand Pharma expects to receive USD 700 million in milestone payments from Roche in 2026, contributing to Zealand Pharma's strong financial position.
Importance 20 Sentiment 0
exch
Nasdaq Copenhagen
The share buy-back program will be carried out on Nasdaq Copenhagen, where Zealand Pharma's shares are quoted.
Importance 10 Sentiment 0
curr
Denmark — Danish krone
The share buy-back program is valued at DKK 1.3 billion, indicating the currency of the transaction.
Importance 10 Sentiment 0
cnt
United States
Zealand Pharma's cash position is USD 2.3 billion and it expects USD 700 million in milestone payments from Roche, indicating the currency of its financial reporting and expected inflows.
Importance 10 Sentiment 0
cnt
Denmark
Zealand Pharma is headquartered in Copenhagen, Denmark, indicating the geographical base of the company initiating the buy-back.
Importance 5 Sentiment 0
cnt
United States
Zealand Pharma has a U.S. presence in Boston, Massachusetts, indicating its international operational scope.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.